<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Head and neck cancer &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/head-and-neck-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 16 Jan 2026 09:13:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Head and neck cancer &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Nanomedicine: Promoting Equity in Head and Neck Cancer Care</title>
		<link>https://bioengineer.org/nanomedicine-promoting-equity-in-head-and-neck-cancer-care/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 16 Jan 2026 09:13:23 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Brazil` **Bu etiketlerin seçilme nedenleri:** 1. **Nanomedicine:** Makalenin temel teknolojik odağı ve ana araştırma konusu. 2. **Head and Neck Cancer:** Makalenin spes]]></category>
		<category><![CDATA[Cost Reduction]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[health equity]]></category>
		<category><![CDATA[healthcare equity]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket (virgülle ayrılmış): `Nanomedicine]]></category>
		<category><![CDATA[Nanomedicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/nanomedicine-promoting-equity-in-head-and-neck-cancer-care/</guid>

					<description><![CDATA[In a groundbreaking study that explores the intersection of nanomedicine and public health, researchers L.M. de Andrade and L.O. Ladeira present a compelling case for the integration of advanced technologies in the treatment of head and neck cancers in Brazil. As the nation grapples with significant healthcare disparities, this research sheds light on how innovative [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317434</post-id>	</item>
		<item>
		<title>Co-Design Framework Identifies Priorities for Head and Neck Cancer Patients</title>
		<link>https://bioengineer.org/co-design-framework-identifies-priorities-for-head-and-neck-cancer-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 12 Jan 2026 09:22:26 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Chronic illness management** **Açıklama:** 1. **Co-design:** Çalışmanın temel metodolojisini ve hasta katılımı yaklaşımını doğrudan vurgular. 2. **Head and neck cancer:** Ara]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[Makale içeriğine ve ana temalarına göre en uygun 5 etiket: **Co-design]]></category>
		<category><![CDATA[Patient priorities]]></category>
		<category><![CDATA[patient-centered care]]></category>
		<guid isPermaLink="false">https://bioengineer.org/co-design-framework-identifies-priorities-for-head-and-neck-cancer-patients/</guid>

					<description><![CDATA[In a groundbreaking study set to be published in 2026, researchers including Achinanya, Bryant, and Payne have delved into the complex needs of patients grappling with incurable head and neck cancer. This type of cancer not only poses a significant challenge due to its physical manifestations but also brings emotional and psychological turmoil. The innovative [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316022</post-id>	</item>
		<item>
		<title>Evaluating Language Models in Oral Health Reporting</title>
		<link>https://bioengineer.org/evaluating-language-models-in-oral-health-reporting/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 20 Dec 2025 15:47:10 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI Accuracy in Healthcare]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[İşte 5 uygun etiket (virgülle ayrılmış): **Large Language Models]]></category>
		<category><![CDATA[Medical Communication** **Açıklama:** 1. **Large Language Models:** Makalenin temel araştırma konusu olan teknolojiyi doğrudan belirtir. 2. **Head and Neck Cancer:** Çalışmanın odak]]></category>
		<category><![CDATA[Oral Health Reporting]]></category>
		<guid isPermaLink="false">https://bioengineer.org/evaluating-language-models-in-oral-health-reporting/</guid>

					<description><![CDATA[Researchers are increasingly turning to artificial intelligence, particularly large language models, to navigate the complexities of medical communication. A recent study led by Rast, Wiegand, and Biermann explores this intersection, focusing on how these sophisticated systems perform in reporting oral health concerns and side effects related to head and neck cancers. This pioneering research not [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">309863</post-id>	</item>
		<item>
		<title>Advances in Immunotherapy for Resectable Head-Neck Cancer</title>
		<link>https://bioengineer.org/advances-in-immunotherapy-for-resectable-head-neck-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 12 Dec 2025 09:52:41 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[immune checkpoint inhibitors** **Açıklama:** 1. **immunotherapy:** Makalenin ana konusu ve devrim niteliğindeki gelişmelerin odağı. 2. **head and neck cancer:** Araştırmanın spes]]></category>
		<category><![CDATA[Makale içeriğine ve ana temalarına göre en uygun 5 etiket: **immunotherapy]]></category>
		<category><![CDATA[Neoadjuvant immunotherapy]]></category>
		<category><![CDATA[resectable]]></category>
		<guid isPermaLink="false">https://bioengineer.org/advances-in-immunotherapy-for-resectable-head-neck-cancer/</guid>

					<description><![CDATA[In recent years, the landscape of cancer treatment has undergone a revolutionary transformation with the introduction and advancement of immunotherapy. Among the various malignancies responsive to these novel approaches, head and neck squamous cell carcinoma (HNSCC) stands out due to its distinct biological behavior and historically poor outcomes in advanced stages. Groundbreaking research conducted by [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">306629</post-id>	</item>
		<item>
		<title>TRIML2 Drives Malignancy in Head and Neck Cancer</title>
		<link>https://bioengineer.org/triml2-drives-malignancy-in-head-and-neck-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 16 Nov 2025 10:27:21 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cancer progression]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[immune evasion]]></category>
		<category><![CDATA[TRIML2]]></category>
		<category><![CDATA[Wnt Signaling]]></category>
		<guid isPermaLink="false">https://bioengineer.org/triml2-drives-malignancy-in-head-and-neck-cancer/</guid>

					<description><![CDATA[In the intricate realm of cancer research, new findings emerge that could reshape our understanding of head and neck squamous cell carcinoma (HNSCC), a prevalent and challenging disease. A recent publication by Luo et al. sheds light on the role of TRIML2 in promoting the aggressive characteristics of this type of cancer. Their research uncovers [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">297529</post-id>	</item>
		<item>
		<title>Scientists Create a Minimally Invasive, More Accurate Technique to Evaluate Immunotherapy Success</title>
		<link>https://bioengineer.org/scientists-create-a-minimally-invasive-more-accurate-technique-to-evaluate-immunotherapy-success/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 22 Oct 2025 20:23:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[immune checkpoint blockade]]></category>
		<category><![CDATA[immunotherapy prediction]]></category>
		<category><![CDATA[immunotherapy success prediction]]></category>
		<category><![CDATA[liquid biopsy technique]]></category>
		<category><![CDATA[minimally invasive monitoring]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[predictive biomarkers]]></category>
		<guid isPermaLink="false">https://bioengineer.org/scientists-create-a-minimally-invasive-more-accurate-technique-to-evaluate-immunotherapy-success/</guid>

					<description><![CDATA[Immunotherapy has revolutionized the landscape of cancer treatment, transforming previously incurable malignancies into potentially manageable diseases by harnessing the patient’s immune system. Despite its monumental promise, a persistent challenge remains: the unpredictable and inconsistent response rates among patients. Addressing this critical issue, researchers at the Cancer Center at Illinois, in collaboration with experts at the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">285404</post-id>	</item>
		<item>
		<title>Predicting Radiation Dermatitis in Head, Neck Cancer</title>
		<link>https://bioengineer.org/predicting-radiation-dermatitis-in-head-neck-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 22 Oct 2025 09:56:41 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[concurrent chemoradiotherapy]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[hematological biomarkers]]></category>
		<category><![CDATA[nomogram prediction model]]></category>
		<category><![CDATA[radiation dermatitis]]></category>
		<guid isPermaLink="false">https://bioengineer.org/predicting-radiation-dermatitis-in-head-neck-cancer/</guid>

					<description><![CDATA[In a groundbreaking study published in BMC Cancer, researchers have developed a highly predictive nomogram model designed to assess the severity of radiation dermatitis (RD) in patients with locally advanced head and neck cancer (HNC) undergoing concurrent chemoradiotherapy. Radiation dermatitis poses a significant clinical challenge due to the heightened sensitivity of the skin in the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">284963</post-id>	</item>
		<item>
		<title>Exploring Digital Nutrition Care in Head and Neck Cancer</title>
		<link>https://bioengineer.org/exploring-digital-nutrition-care-in-head-and-neck-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Oct 2025 11:44:40 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[digital health interventions]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[nutritional management]]></category>
		<category><![CDATA[patient-caregiver perspectives]]></category>
		<category><![CDATA[qualitative research in healthcare]]></category>
		<guid isPermaLink="false">https://bioengineer.org/exploring-digital-nutrition-care-in-head-and-neck-cancer/</guid>

					<description><![CDATA[Recent research into the nutritional management of head and neck cancer patients highlights a growing awareness of the importance of digital tools in providing seamless care. This qualitative study, led by an international team including Severinsen, Varsi, and Andersen, captures the experiences of patients, family caregivers, and healthcare professionals regarding nutritional follow-up during the treatment [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">282732</post-id>	</item>
		<item>
		<title>SNMMI Image of the Year: Novel Immuno-PET Tracer Outperforms FDG PET in Predicting PD-L1 Expression in Head and Neck Cancer</title>
		<link>https://bioengineer.org/snmmi-image-of-the-year-novel-immuno-pet-tracer-outperforms-fdg-pet-in-predicting-pd-l1-expression-in-head-and-neck-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 24 Jun 2025 01:14:28 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[Immuno-PET]]></category>
		<category><![CDATA[PD-L1 imaging]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[SNMMI 2025]]></category>
		<guid isPermaLink="false">https://bioengineer.org/snmmi-image-of-the-year-novel-immuno-pet-tracer-outperforms-fdg-pet-in-predicting-pd-l1-expression-in-head-and-neck-cancer/</guid>

					<description><![CDATA[A groundbreaking advancement in molecular imaging has recently emerged from the realm of nuclear medicine, promising to redefine how clinicians assess and manage head and neck cancers. At the forefront of this innovation is a novel peptide-based PET tracer, ^18F-AlF-NOTA-PCP2, designed specifically to target programmed death-ligand 1 (PD-L1), a crucial immune checkpoint protein frequently overexpressed [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">250215</post-id>	</item>
	</channel>
</rss>
